编者按：2025年3月12日-15日，第19届St.Gallen早期乳腺癌研讨会（SGBCC）盛大召开。会上，中国临床肿瘤学会（CSCO）与SGBCC打造中国专场——“Voice of China”，展示了中国乳腺癌领域在临床研究、基础研究、转化医学、影像组学等多方面进展，吸引了众多国际专家的广泛讨论。《肿瘤瞭望》于会议现场特别邀请两位专场主席——SGBCC主席团成员、CSCO候任理事长、解放军总医院江泽飞教授与SGBCC大会主席、奥地利维也纳医科大学综合癌症中心Michael Gnant教授——展开深度对话，展望中西合璧的未来发展。

 

From March 12 to 15，2025，the 19th St.Gallen International Breast Cancer Conference(SGBCC)was held with great success.During the conference，the Chinese Society of Clinical Oncology(CSCO)and SGBCC jointly organized the"Voice of China"session，showcasing China’s advancements in clinical research，basic science，translational medicine，and radiomics within the breast cancer field，which sparked vibrant discussions among global experts.“Oncology Frontier”invited the co-chairs of this session—Professor Jiang Zefei(St.Gallen International Consensus panel Member，CSCO President-Elect，Chinese PLA General Hospital)and Professor Michael Gnant(SGBCC Congress Chair，Comprehensive Cancer Center，Medical University of Vienna)—to engage in a profound dialogue on the future of Sino-global collaboration.

 

 

Oncology Frontier：The 2025 SGBCC has commenced.How has SGBCC influenced breast cancer diagnosis and treatment globally，including in China，over recent years?

 

Michael Gnant教授：SGBCC的整体影响在于定义了乳腺癌的标准治疗方案。它的重点并不是发布新的研究数据或最新试验结果，而是在全球视角下，探讨不同亚组患者的最佳治疗策略。SGBCC在亚洲备受关注，让我感到欣喜的是，近年来越来越多的中国专家积极参与其中，不仅增强了大会的影响力，也进一步凸显了其对中国患者和临床医生的指导意义。

 

Professor Michael Gnant:The overall impact of the St.Gallen Breast Cancer International Conference is that it sets the standard of care.So，it’s not so much about new data or new studies.It’s more about what should be done for each patient subgroup from a global perspective—and that’s something that is particularly well-respected in Asia.With increasing Chinese contributions，which I’m very happy about，I think it’s also of growing relevance to Chinese patients and physicians.

 

江泽飞教授：诚然如此。中国专家在很多年前便已开始关注SGBCC，彼时我们只能在台下听讲。后来，我们逐渐参与其中，有机会代表中国团队在主席台发出中国声音。如今，非常高兴SGBCC主席团有来自中国大陆的4位专家以及中国台湾省的1位同道，我们可以分别主持不同专场，并且在投票中表达自己的临床经验、观点和看法。

 

Professor Zefei Jiang:Indeed，Chinese scholars have been engaged with SGBCC for years，initially as observers.Now actively contributing clinical expertise at major forums，these specialists demonstrate China’s growing role in global healthcare.Within the St.Gallen panel’s international cohort，Chinese scholars constitute a significant contingent.Five specialists from different parts of China，including four from the mainland and one from the Taiwan region of China，are advancing the integration of China’s clinical wisdom into global healthcare frameworks through structured academic exchanges.

 

 

Oncology Frontier：The inaugural"Voice of China"session was a highlight.What distinguishes its significance?

 

江泽飞教授：非常感谢各位媒体朋友对大会的关注。非常荣幸能在SGBCC大会上安排专属于中国的“Voice of China”专场，并与徐兵河院士、邵志敏教授和殷咏梅教授以及国际知名专家共同主持此次会议。SGBCC主席Michael Gnant教授、欧洲肿瘤内科学会（ESMO）候任主席Giuseppe Curigliano教授以及各领域的知名专家参与了此次会议。

 

会上，我们向国际友人介绍了中国临床肿瘤学会（CSCO）以及中国临床肿瘤学会乳腺癌专家委员会（CSCO BC）；殷咏梅教授介绍了一系列中国原创研究；刘强教授分享了肿瘤标记物的国际进展和自己开展的工作；江一舟教授代表邵志敏教授团队发布了乳腺癌转化医学的研究报告；王坤教授针对早期乳腺治疗的热点问题分享他们团队在影像组学方面的工作，充分展现了近年来中国学者在乳腺临床研究和转化研究方面的成果，并与众多国际同行进行了良好的互动与交流。“Voice of China”专场既让中国专家能够在国际舞台发声，也让国际专家能够了解到中国的学术进展。

 

在此，非常感谢各位媒体朋友对“Voice of China”专场的关心和支持，感谢恒瑞等团体会员单位的大力支持，感谢他们为会场带来的中国创新药品、特色摆件、小点心等中国元素的布置，让会场更添特色。

 

Prof.Zefei Jiang:We extend our heartfelt gratitude to all media colleagues for your attention to this conference.It is our great honor to host the dedicated"Voice of China"session at SGBCC，co-chaired alongside Prof.Binghe Xu，Prof.Zhimin Shao，Prof.Yongmei Yin，and internationally renowned experts.The session also saw the participation of Prof.Michael Gnant(SGBCC Congress Chair)，Prof.Giuseppe Curigliano(ESMO President-Elect)，and distinguished scholars across various fields.

 

During the session，we introduced the CSCO and CSCO Breast Cancer Committee(CSCO BC)to global peers.Prof.Yongmei Yin presented a series of groundbreaking Chinese-led studies，while Prof.Qiang Liu shared international advancements in tumor biomarkers alongside his team’s innovative work.Prof.Yizhou Jiang，representing Prof.Zhimin Shao’s research group，unveiled transformative findings in breast cancer translational medicine.Prof.Kun Wang highlighted his team’s cutting-edge radiomics research addressing hot topics in early-stage breast cancer treatment.These presentations not only demonstrated the remarkable progress Chinese scholars have achieved in clinical and translational research but also fostered vibrant interactions with international experts.The"Voice of China"session served as a dual platform:amplifying China’s academic contributions on the global stage while enabling international colleagues to gain deeper insights into China’s scientific advancements.

 

We sincerely thank all media partners for your unwavering support of the"Voice of China"session.Special recognition goes to institutional members like Hengrui Pharmaceuticals for their exceptional contributions in enriching the venue with distinctive Chinese cultural elements—showcasing innovative therapies，traditional artifacts，and authentic delicacies—which added a unique charm to the event.

 

Michael Gnant教授：“Voice of China”专场是SGBCC首次举办的中国专场，也是SGBCC与CSCO紧密合作的成果。我们曾与江泽飞教授、殷咏梅教授等中国专家共同探讨过如何加强中国专家与SGBCC的互动，并推动全球最新的乳腺癌研究成果更好地服务于中国的临床实践。从今年的参会情况来看，我们的努力取得了显著成效——本届大会有200余位中国专家参会，而两年前这一数字仅为20人左右，这充分体现了我们合作的成功。

 

“Voice of China”专场，为中国年轻一代极具潜力的未来学术领袖，提供了一个向国际专家展示研究数据并深入探讨的宝贵机会。我认为，中国在乳腺癌领域对全球学术研究的影响力正在不断提升，而这次专场正好为大家提供了交流、讨论和互动的机会，这对所有参会者而言，无疑是一次难得的收获。

 

Prof.Michael Gnant:The inaugural"Voice of China"initiative we launched this year represents a pivotal collaboration between the SGBCC and CSCO.Through close coordination with Chinese experts like Zefei Jiang and Yongmei Yin，we sought to strengthen two-way engagement:enhancing Chinese experts’participation in SGBCC dialogues while fostering global insights into China’s breast cancer landscape.These efforts have yielded remarkable results—this year’s conference hosts 200 Chinese experts，a tenfold increase from the 20 attendees two years prior.

 

The"Voice of China"session provides a unique platform，particularly for emerging leaders with high potential，to present cutting-edge research to a world-class faculty and engage in cross-border dialogue.China’s growing contributions to global breast cancer knowledge are undeniable，and this forum offers invaluable opportunities for collective learning，critical discussion，and intellectual exchange—benefits that extend to all participants.

 

 

Oncology Frontier：How is Chinese clinical research reshaping global paradigms?In what ways will SGBCC reciprocate to advance clinical practice in China?

 

Michael Gnant教授：中国的研究机构享有极高的国际声誉，如中国医学科学院肿瘤医院、复旦大学附属肿瘤医院等都在乳腺癌研究领域都做出了重要贡献。中国人口基数庞大，实现高效的乳腺癌早期筛查无疑是一项巨大的挑战，需要不断优化。而在我所在的国家小得多，也要容易得多。我认为，中国与SGBCC的持续的交流至关重要。我经常到中国访问，也与中国的专家们建立了深厚合作关系和友谊。未来，我们将看到全球的医学知识不断融入中国的临床实践，比如更多采用保乳术而非全乳切除；同时，我们也将看到中国的研究成果逐步融入全球乳腺癌的治疗规范，比如复旦大学附属肿瘤医院提出的TNBC复旦分型和Luminal乳腺癌等。

 

Prof.Michael Gnant:Chinese research institutions command significant international respect，particularly premier institutions like the Chinese Academy of Medical Sciences in Beijing and Fudan University in Shanghai，which have made substantial contributions to the field.However，given the scale of China’s population，certain challenges persist—notably in early detection systems where optimizing screening protocols to enable less invasive interventions remains critical.Implementing nationwide strategies for nearly 1.5 billion people presents complexities far beyond those faced in smaller nations，though international collaboration offers a viable pathway forward.

 

Through my extensive travels and collaborations in China，I’ve observed a dynamic two-way exchange emerging:Global best practices，such as prioritizing breast-conserving surgeries over mastectomies，are increasingly integrated into local clinical protocols.Concurrently，Chinese innovations—like Fudan University’s molecular subtyping system for triple-negative and hormone receptor-positive breast cancers—are beginning to reshape global treatment paradigms.This symbiotic relationship exemplifies how cross-border partnerships can elevate standards of care while fostering scientific progress on a global scale.

 

 

Oncology Frontier：Today，the"Voice of China"resonates at SGBCC;tomorrow，SGBCC will embark on a roadshow in China.What are your expectations for future collaborations between SGBCC and CSCO?

 

江泽飞教授：在SGBCC结束后，我们将在国内迅速组织SGBCC的会后会，还在4月份的全国乳腺癌大会中特别安排了SGBCC专场，届时我们将邀请SGBCC大会主席Michael Gnant教授，出席“Voice of China”的国际专家，以及徐兵河院士、邵志敏教授、殷咏梅教授等国内外知名专家共同讨论SGBCC热点，以期及时传递国际会议信息，让更多中国同道第一时间了解国际进展，助力中国乳腺癌临床实践和患者管理能力的提升。

 

Prof.Zefei Jiang:Following the conclusion of SGBCC，we will swiftly organize domestic post-SGBCC symposiums in China.Additionally，a dedicated SGBCC session has been specially incorporated into the agenda of the China Breast Cancer Conference in April.This session will convene global thought leaders，including Prof.Michael Gnant(SGBCC Congress Chair)，international faculty from the"Voice of China"session，and renowned experts such as Ptof.Binghe Xu，Prof.Zhimin Shao，and Prof.Yongmei Yin，to dissect key SGBCC highlights.

 

These initiatives aim to ensure the timely dissemination of global insights from the conference，enabling Chinese clinicians to stay abreast of international advancements.By fostering knowledge exchange between Chinese and global peers，we seek to elevate the standards of breast cancer care and patient management across China.

 

Michael Gnant教授：我十分期待我们在科学研究与临床实践的交流互动能够持续推进。在过去的两年里，我访问了北京、上海、南京、西安、成都、天津等中国城市。今年，我还有三次前往中国的计划，期待能结识更多新朋友，访问更多具有丰富临床经验、科研能力不断提升、且管理着庞大患者群体的团队。未来，全球医学界将从中国的研究中汲取更多经验，也能我们的临床实践也能为中国带来一些启发，我对此充满期待。

 

Prof.Michael Gnant:I believe the expectation is that this ongoing dialogue—encompassing both scientific advancements and clinical practice data exchange—will continue to deepen.Over the past two years，I’ve had the privilege of visiting numerous cities，including Beijing，Shanghai，Nanjing，Xi’an，Chengdu，and Tianjin.With three planned trips to China this year，I eagerly anticipate engaging with new teams who possess not only vast clinical experiences from treating large patient populations but also growing scientific influence.

 

Through these interactions，I envision a reciprocal learning process:The global medical community stands to gain significantly from China’s innovations，while Chinese practitioners may also find value in international experiences.This mutual exchange of knowledge promises to elevate standards of care worldwide，and I look forward to contributing to this collaborative ecosystem.